Document is current
Any future updates will be listed below
-
Authors
Shiina, Sara
Ueda, Tatsuki https://orcid.org/0000-0002-6705-5626
Iriguchi, Shoichi https://orcid.org/0009-0005-9228-2352
Uemura, Yasushi
Kaneko, Shin https://orcid.org/0000-0003-2291-4586
-
Funding
Funding for this research was provided by:
MEXT | Japan Science and Technology Agency (JPMJSP2110)
Takeda-CiRA collaboration program
- License Information
-
More Information
Article History
Received: 20 February 2024
Accepted: 19 December 2025
First Online: 9 January 2026
Competing interests
: The authors declare the following competing interests: Shin Kaneko is the founder, shareholder, and director of Shinobi Therapeutics, Inc., and has received research funding from Shinobi Therapeutics, Inc., Takeda Pharmaceutical Co., Ltd., Astellas Co., Ltd., Terumo Co., Ltd., Mitsui-soko Co., Ltd. and KOTAI Biotechnologies, Co., Ltd.
